GESTALT CLINICAL TRIAL for PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMAS (GBMs) | ENROLLING NOW
All clinical trial participants will receive both GammaTile® and the Stupp protocol.
Named after its founder, the Stupp protocol consists of external beam radiation therapy (EBRT) and oral chemotherapy with Temodar®, also called temozolomide, or TMZ.1 EBRT is delivered to the brain tumor or the area where the brain tumor was removed. Radiation and chemotherapy are combined to optimize treatment results.1
No, the total radiation administered in this clinical trial from both GammaTile and EBRT is within standard radiation treatment levels.
Prior to your brain tumor–removal surgery, you’ll need to complete these study enrollment steps:
1. Schedule an appointment with the GESTALT Clinical Study team to confirm that you qualify for the study and take the screening tests.
2. Sign the informed consent study form.
3. Take a pregnancy test if you are a female of childbearing age.
4. Answer a questionnaire about your quality of life.
5. Take brain function assessments.
Next, the GESTALT Clinical Team will schedule your surgery, and you will be on track to receive your treatments. The first follow-up visit will be 28 +3 days after the start of cycle 4 of adjuvant temozolomide. Follow-up visit frequency will be:
The GESTALT Trial is sponsored by GT Medical Technologies, Inc., the makers of GammaTile®. Please discuss the risks and benefits of participating in this clinical trial with your care team.
Indication: GammaTile is indicated as a treatment for patients with newly diagnosed malignant intracranial neoplasms and recurrent intracranial neoplasms.
Safety Information: The potential for, and symptoms of, adverse events related to radiation exposure vary depending on the radiosensitivity of the exposed tissue, the amount of radiation delivered, and the placement of GammaTile(s). GammaTile should not be used for patients with a known history of hypersensitivity to bovine-derived materials.
GESTALT CLINICAL TRIAL for PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMAS (GBMs)
©2022 GT Medical Technologies, Inc. I All rights reserved I GammaTile is a registered trademark of GT Medical Technologies, Inc.